How to Value a Medicare-Heavy Physical Therapy Practice in 2026

Physical therapy is one of the most actively consolidated segments in outpatient healthcare, but the multiples vary dramatically based on payer mix. A commercial- heavy orthopedic-referral PT clinic in a dense suburban market can trade at 8-10x EBITDA; a Medicare-heavy clinic with the same revenue and margin profile might trade at 4-6x. I've watched sellers walk away from deals because they expected "industry multiples" without understanding that their payer mix put them in a different bucket entirely.

If you run a PT clinic where 50%+ of visits come from traditional Medicare or Medicare Advantage, here's what buyers actually pay, what the unique regulatory landscape means for your valuation, and how to position the clinic to capture the best multiple your payer mix will support.

The Multiples: What Medicare PT Actually Trades For

Here's the honest range I see on closed transactions:

• Solo clinic, 60%+ Medicare, sub-$1M revenue: 2-3.5x SDE to a private buyer. See SDE vs EBITDA for how these methods compare.
• Single-location, 50%+ Medicare, $1-2.5M revenue: 4-6x EBITDA to a regional PT consolidator.
• Multi-location Medicare-heavy platform, $3M+ revenue: 6-9x EBITDA to a PE-backed platform like Upstream Rehab, Confluent Health, Ivy Rehab, H2 Health, or Athletico (for the right markets).
• Clinic with strong MA value-based contracts: 7-10x EBITDA — the MA premium exists in PT just like it does in primary care, though the volume is smaller.

The commercial-heavy comparable would be roughly 1.5-2x higher across all of these brackets. The difference is structural and won't close no matter how well you run the clinic.

Why Medicare PT Is Structurally Discounted

The therapy cap and KX modifier dynamics. Medicare eliminated the hard therapy cap in 2018, but the threshold-with-documentation structure remains. In 2026, the KX modifier threshold sits around $2,410 for PT/SLP combined. Above that, you have to attest that continued therapy is medically necessary. Above the targeted medical review threshold ($3,000+), you're in audit territory. Buyers model compliance risk, potential clawbacks, and the administrative burden of documentation. That shaves the multiple.

Multiple Procedure Payment Reduction (MPPR). CMS reduces payment for the second and subsequent units of therapy performed on the same day. This directly compresses per-visit revenue in a way that commercial payers generally don't. A clinic whose treatment model depends on multiple timed codes per visit earns meaningfully less per Medicare visit than per commercial visit.

Annual fee schedule cuts. The Medicare Physician Fee Schedule has been cut or frozen in most recent years. The 2025 schedule reduced the conversion factor by 2.83%, and PT codes absorbed the full reduction. Buyers model forward cuts when they underwrite, and they discount the cash flows accordingly.

Supervision and assistant limits. Medicare pays assistant (PTA)-provided services at 85% of the PT rate under the CQ modifier rule. Commercial payers generally don't impose this differential. In a clinic where PTAs deliver a meaningful share of care, the 15% differential is a direct hit to revenue and EBITDA.

Productivity requirements are brutal. A PT clinic can only be profitable on Medicare if therapists deliver high volume — typically 10-14 visits per day per PT with 2-3 concurrent patients when permitted. Commercial clinics can make money at 8-10 visits per day. The Medicare model depends on operational discipline that's hard to maintain and even harder to scale.

The Medicare Advantage Wrinkle

Medicare Advantage plans pay PT differently than traditional Medicare, and it matters for valuation. MA plans often use utilization management, require prior authorization, cap visits per episode, and in some markets are shifting to value-based arrangements with primary care groups that subcontract PT.

A clinic with strong MA contracts — particularly capitated or bundled episode arrangements through primary care groups or orthopedic surgery bundles — can earn premium multiples even with heavy senior population exposure. The reason is the same as in primary care: predictable, risk-contracted revenue is worth more than fee-for-service exposure.

The catch is that MA prior auth denials hammer operational efficiency. A clinic where 25% of MA episodes require peer-to-peer reviews or appeals has a higher labor cost per visit than the raw payment data suggests. Buyers see through this during diligence.

What Buyers Actually Underwrite

• Visits per clinician per day: 11-13 is the target for a Medicare-heavy clinic. Below 9, the model doesn't work at Medicare rates.
• Net revenue per visit: $85-$110 is typical for heavy Medicare mix; $125+ is excellent.
• Cancellation and no-show rate: under 12% is strong; over 18% signals operational issues.
• Payer mix stability: buyers want to see the Medicare percentage steady, not growing as a share. A clinic trending from 45% Medicare to 65% over three years is implicitly losing its commercial book.
• Referral source concentration: if 40%+ of referrals come from one physician group, that's a concentration risk that caps the multiple.
• KX modifier usage patterns: excessive KX attestation can trigger audit flags. Clean usage patterns matter.
• Staff PT compensation as % of revenue: 45-52% is typical. Above 55%, the clinic is underwater on Medicare unit economics.

Who Buys These Clinics

The buyer pool for Medicare-heavy PT is narrower than for commercial-heavy clinics but still well-represented:

Regional PT platforms: Upstream Rehab, Ivy Rehab, Confluent Health (Select Physical Therapy), Athletico, H2 Health, US Physical Therapy, ATI Physical Therapy, and dozens of smaller PE-backed regional groups all buy clinics. They'll buy Medicare-heavy clinics, but at lower multiples and with more aggressive earn-out structures tied to maintaining volume and compliance.

Health systems: hospitals and ortho-focused systems buy PT clinics to capture the post-surgical rehab episode and to control the bundled payment economics for joint replacements. They pay modest multiples but offer deal certainty and simple structures.

Orthopedic practice groups: large ortho groups (particularly PE-backed ones like OrthoVirginia, Rothman, Resurgens) sometimes buy PT clinics to internalize referrals. The multiples are moderate, but the strategic fit can be strong.

Home health and senior-focused platforms: for clinics that can pivot toward home-based PT, senior living partnerships, or SNF contracts, home health consolidators may be the best buyer. The multiples differ and the deal structure is different, but the buyer universe opens up.

What Kills Value in a Medicare PT Clinic

Low productivity. If your PTs are delivering 7-9 visits per day at Medicare rates, the clinic is barely profitable and the multiple will reflect it. Operational discipline on scheduling, cancellations, and treatment templating matters more in Medicare-heavy clinics than anywhere else in PT.

Single referral source dependency. A clinic where one ortho group sends 50%+ of referrals is one retirement or competing clinic opening away from disaster. Buyers discount heavily.

Owner as lead clinician. If the selling PT is the top producer and most of the Medicare patients see the owner personally, the transition risk is real. Buyers will structure earn-outs that protect against attrition — meaning you're working for 2-3 years post-close to earn the full price.

Compliance blind spots. Medicare audits hit PT clinics hard. Incomplete documentation, missing plan of care signatures, unsupported KX modifier usage, and PTA supervision errors are all common findings. Any open audit or history of clawbacks will show up in diligence and will either compress the price or kill the deal.

Short lease. Same story as every other healthcare sale — a lease with under 3 years remaining and no renewal option will hammer your valuation.

How to Maximize Value Before Selling

Drive productivity up without sacrificing quality. Small operational changes — 15-minute cancellation cushions, group therapy sessions where permitted, efficient treatment templates — can move visits per clinician per day from 10 to 12 and transform the EBITDA margin.

Diversify referral sources. Build relationships with 4-6 different physician groups before going to market. Referral diversification is one of the fastest ways to move from a 4x to a 6x multiple.

Clean up compliance. Hire a compliance consultant to audit your charts, KX modifier usage, and PTA supervision documentation 12 months before sale. Clean audit history is worth a full turn of EBITDA.

Pursue MA value-based contracting. If MA plans in your market are offering bundled episode or value-based arrangements, getting in early gives you the higher-multiple positioning when you sell.

Review your payer mix strategically. If you're currently 65% Medicare and can push commercial mix to 50% over 18 months through targeted marketing to younger referral sources, the valuation difference can be enormous. See the pre-sale prep timeline for sequencing.

The Bottom Line

Medicare-heavy PT clinics are valuable businesses, but they're priced in a different segment of the PT market than their commercial-heavy peers. The sellers who do best are the ones who accept that reality, optimize their operations for Medicare unit economics, and either diversify payer mix or position the clinic to fit a specific buyer's strategic need. The ones who walk into a sale expecting 8x EBITDA because "that's what PT trades at" end up disappointed. Know your segment, know your buyers, and build the clinic they're actually willing to pay up for.